1 Janeway CA, Travers P. Immunobiology: The immune system in health and disease. New York: Garland Publishing, 1997, p.
2 Janeway CA, Travers P. Immunobiology: The immune system in health and disease. New York: Garland Publishing, 1997, pp. 4:3, 9:6.
3 Kobayashi T. [Role of NK cells in lung metastasis immunosurveillance.] Gan To Kagaku Ryoho 1989 Apr; 16(4 Pt 2-1):1233-45.
4 Woodruff MF. The cytolytic and regulatory role of natural killer cells in experimental neoplasia. Biochim Biophys Acta 1986 Aug 5; 865(1):43-57.
5 Kim S, Iizuka K, Aguila HL, et al. In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc Natl Acad Sci USA 2000 Mar 14; 97(6):2731-6.
6 Dithmar SA, Rusciano DA, Armstrong CA, et al. Depletion of
NK cell activity results in growth of hepatic micrometastases in a murine ocular melanoma model. Curr Eye Res 1999 Nov; 19(5):426-31.
7 Whiteside TL, Vujanovic NL, Herberman RB. Natural killer cells and tumor therapy. Curr Top Microbiol Immunol 1998; 230:221-44.
8 Herberman R, Santoni A. Regulation of NK-cell activity. In
Biological responses in cancer: Progress toward potential applications. Vol 1. Mihich E, ed. New York: Plenum Press, 1982.
9 Diefenbach A, Raulet DH. Natural killer cells: Stress out, turn on, tune in. Curr Biol 1999 Nov 18; 9(22):R851-3.
10 Holleb AI, Fink DJ, Murphy GP. American Cancer Society textbook of clinical onocology. Atlanta: American Cancer Society, 1991.
11 Penn I. Principles of tumor immunity: Immunocompetence and cancer. In Biologic therapy of cancer. DeVita V, Hellman S, Rosenberg S, eds. Philadelphia: JB Lippincott, 1991.
12 Wojtowicz-Praga S. Reversal of tumor-induced immunosuppression: A new approach to cancer therapy [see comments]. J Immunother 1997 May; 20(3):165-77.
13 Tung YC, Lin KH, Chu PY, et al. Detection of human papilloma virus and Epstein-Barr virus DNA in nasopharyngeal carcinoma by polymerase chain reaction. Kao Hsiung I Hsueh Ko Hsueh Tsa Chih 1999 May; 15(5):256-62
14 Ohtsubo H, Arima N, Tei C. Epstein-Barr virus involvement in T-cell malignancy: Significance in adult T-cell leukemia. Leuk Lymphoma 1999 May; 33(5-6):451-8.
15 Flaitz CM, Hicks MJ. Molecular piracy: The viral link to carcinogenesis. Oral Oncol 1998 Nov; 34(6):448-53.
16 McCance DJ, Kalache A, Ashdown K, et al. Human papillomavirus types 16 and 18 in carcinomas of the penis from Brazil. Int J Cancer 1986 Jan 15; 37(1):55-9.
17 Levi JE, Rahal P, Sarkis AS, Villa L. Human papillomavirus DNA and p53 status in penile carcinomas. Int J Cancer 1998 Jun 10; 76(6):779-83.
18 Ylitalo N, Sorensen P, Josefsson AM, et al. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: A nested case-control study. Lancet 2000 Jun 24; 355(9222):2194-8.
19 Josefsson AM, Magnusson PK, Ylitalo N, et al. Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: A nested case-control study. Lancet 2000 Jun 24; 355(9222):2189-93.
20 Tuttle TM. Oncogene products represent potential targets of tumor vaccines. Cancer Immunol Immunother 1996 Nov; 43(3):135-41.
21 Chen HL, Carbone DP. p53 as a target for anti-cancer immunotherapy. Mol Med Today 1997 Apr; 3(4):160-7.
22 Calabresi P, Schein P. Medical oncology. 2nd ed. New York: McGraw-Hill, 1993, pp. 325-6.
23 Holland JF, Frei E, Bast R, et al. Cancer medicine. 3rd ed. Philadelphia: Lea & Febiger, 1993, p. 187.
24 Calabresi P, Schein P. Medical oncology. 2nd ed. New York: McGraw-Hill, 1993, p. 331.
25 Becker JC, Dummer R, Hartmann AA, et al. Shedding of ICAM-1 from human melanoma cell lines induced by IFN-gamma and tumor necrosis factor-alpha. Functional consequences on cell-mediated cytotoxicity. J Immunol 1991 Dec 15; 147(12):4398-401.
26 Aziz M, Dass TK, Rattan A. Role of circulating immune-complexes as prognostic indicators of lympho-reticular and mesenchymal malignancies in children. J Trop Pediatr 1992 Aug; 38(4):185-8.
27 Wahl LM, Kleinman HK. Tumor-associated macrophages as targets for cancer therapy. J Natl Cancer Inst 1998; 90(21) :1583-4.
28 Kiessling R, Kono K, Petersson M, Wasserman K. Immunosuppression in human tumor-host interaction: Role of cytokines and alterations in signal-transducing molecules. Springer Semin Immunopathol 1996; 18(2):227-42.
29 Lee PP, Yee C, Savage PA, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nature Medicine 1999; 5(6):677-685.
30 Hoover HC, Hanna, MG. Immunotherapy by active specific immunization: Clinical applications. In Biologic therapy of cancer. DeVita VT, Hellman S, Rosenberg S, eds. Philadelphia: JB Lippincott, 1991.
31 Hersh EM, Taylor CW. Immunotherapy by active immunization of the host using nonspecific stimulants and immunomodulators. In Biologic therapy of cancer. De Vita VT, Hellman S, Rosenberg S, eds. Philadelphia: JB Lippincott, 1991.
32 Tannock IF, Hill RP, eds. The basic science of oncology. 2nd ed. New York: McGraw-Hill, 1992, p. 245.
33 Calabresi P, Schein P. Medical oncology. 2nd ed. New York: McGraw-Hill, 1993, p. 334.
34 Nseyo UO, Lamm DL. Immunotherapy of bladder cancer. Semin Surg Oncol 1997 Sep-Oct; 13(5):342-9.
35 Lotze MT, Rosenberg SA. Interleukin-2: Clinical applications. In Biologic therapy of cancer. DeVita VT, Hellman S, Rosenberg SA, eds. Philadelphia: JB Lippincott, 1991.
36 Koretz MJ, Lawson DH, York RM, et al. Randomized study of interleukin 2 (IL-2) alone vs IL-2 plus lymphokine-activated killer cells for treatment of melanoma and renal cell cancer. Arch Surg 1991 Jul; 126(7):898-903.
37 Rosenberg SA. Adoptive cellular therapy: Graft-versus-tumor responses after bone-marrow transplantation. In Biologic therapy of cancer. DeVita VT, Hellman S, Rosenberg SA, eds. Philadelphia: JB Lippincott, 1991.
38 Weiss GR, Margolin KA, Aronson FR, et al. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. J Clin Oncol 1992 Feb; 10(2) :275-81.
39 Kruit WH, Stoter G. The role of adoptive immunotherapy in solid cancers. Neth J Med 1997 Feb; 50(2):47-68.
40 Holland JF, Frei E, Bast R, et al. Cancer medicine. 3rd ed. Philadelphia: Lea & Febiger, 1993, p. 190.
41 Canobbio L, Miglietta L, Boccardo F. Medical treatment of advanced renal cell carcinoma: Present options and future directions. Cancer Treat Rev 1996 Mar; 22(2):85-104.
42 Atkins MB. The treatment of metastatic melanoma with chemotherapy and biologics. Curr Opin Oncol 1997 Mar; 9(2):205-13.
43 Legha SS. Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy. Semin Oncol 1997 Feb; 24(1 Suppl 4):S39-43.
Was this article helpful?
Complete Guide to Preventing Skin Cancer. We all know enough to fear the name, just as we do the words tumor and malignant. But apart from that, most of us know very little at all about cancer, especially skin cancer in itself. If I were to ask you to tell me about skin cancer right now, what would you say? Apart from the fact that its a cancer on the skin, that is.